[go: up one dir, main page]

WO2008151811A3 - Verfahren zur herstellung eines arzneimittels enthaltend vardenafil hydrochlorid trihydrat - Google Patents

Verfahren zur herstellung eines arzneimittels enthaltend vardenafil hydrochlorid trihydrat Download PDF

Info

Publication number
WO2008151811A3
WO2008151811A3 PCT/EP2008/004755 EP2008004755W WO2008151811A3 WO 2008151811 A3 WO2008151811 A3 WO 2008151811A3 EP 2008004755 W EP2008004755 W EP 2008004755W WO 2008151811 A3 WO2008151811 A3 WO 2008151811A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicament
preparation
hydrochloride trihydrate
vardenafil hydrochloride
vardenafil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/004755
Other languages
English (en)
French (fr)
Other versions
WO2008151811A2 (de
Inventor
Sandra Brueck
Nahrup Julia Schulze
Birgit Schnitter
Yogesh S Deshpande
Ganesh Gat
Javed Hussain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ratiopharm GmbH
Original Assignee
Ratiopharm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm GmbH filed Critical Ratiopharm GmbH
Priority to US12/600,446 priority Critical patent/US8772292B2/en
Priority to RU2010100819/15A priority patent/RU2493849C2/ru
Priority to EP08759223A priority patent/EP2170296A2/de
Priority to CA002687500A priority patent/CA2687500A1/en
Publication of WO2008151811A2 publication Critical patent/WO2008151811A2/de
Publication of WO2008151811A3 publication Critical patent/WO2008151811A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung eines Arzneimittels enthaltend Vardenafil Hydrochlorid Trihydrat in fester Form, bei dem Vardenafil Hydrochlorid Trihydrat mit geeigneten pharmazeutischen Hilfsstoffen bei einer Temperatur von ca. 20 °C bis ca. 45 °C verarbeitet wird.
PCT/EP2008/004755 2007-06-12 2008-06-12 Verfahren zur herstellung eines arzneimittels enthaltend vardenafil hydrochlorid trihydrat Ceased WO2008151811A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/600,446 US8772292B2 (en) 2007-06-12 2008-06-12 Process for the preparation of a medicament comprising vardenafil hydrochloride trihydrate
RU2010100819/15A RU2493849C2 (ru) 2007-06-12 2008-06-12 Способ приготовления лекарственного средства, содержащего варденафила гидрохлорида тригидрат
EP08759223A EP2170296A2 (de) 2007-06-12 2008-06-12 Verfahren zur herstellung eines arzneimittels enthaltend vardenafil hydrochlorid trihydrat
CA002687500A CA2687500A1 (en) 2007-06-12 2008-06-12 Process for the preparation of a medicament comprising vardenafil hydrochloride trihydrate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007027067.6 2007-06-12
DE102007027067A DE102007027067A1 (de) 2007-06-12 2007-06-12 Verfahren zur Herstellung eines Arzneimittels enthaltend Vardenafil Hydrochlorid Trihydrat

Publications (2)

Publication Number Publication Date
WO2008151811A2 WO2008151811A2 (de) 2008-12-18
WO2008151811A3 true WO2008151811A3 (de) 2009-03-26

Family

ID=39986037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/004755 Ceased WO2008151811A2 (de) 2007-06-12 2008-06-12 Verfahren zur herstellung eines arzneimittels enthaltend vardenafil hydrochlorid trihydrat

Country Status (6)

Country Link
US (1) US8772292B2 (de)
EP (1) EP2170296A2 (de)
CA (1) CA2687500A1 (de)
DE (1) DE102007027067A1 (de)
RU (1) RU2493849C2 (de)
WO (1) WO2008151811A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806314B2 (en) 2013-12-09 2023-11-07 Respira Therapeutics, Inc. PDE5 inhibitor powder formulations and methods relating thereto

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201028168A (en) * 2008-12-19 2010-08-01 Solvay Pharm Bv Precompacted fast-disintegrating formulations of compounds with a low oral bioavailability
DE102009020888A1 (de) 2009-05-12 2010-11-18 Ratiopharm Gmbh Schmelztablette, enthaltend ein Vardenafil-Salz
CZ303877B6 (cs) 2011-11-24 2013-06-05 Zentiva, K.S. Zpusob prípravy a izolace solí vardenafilu s kyselinami
CZ307091B6 (cs) * 2012-09-14 2018-01-10 Zentiva, K.S. Stabilní farmaceutický přípravek obsahující Vardenafil hydrochlorid
BR112020012239A2 (pt) 2017-12-20 2020-11-24 Klaria Pharma Holding Ab método para preparar um filme mucoadesivo, e, filme mucoadesivo
JP7336241B2 (ja) * 2019-04-02 2023-08-31 富士化学工業株式会社 バルデナフィル含有錠剤の製造方法
CN114948968A (zh) * 2021-02-22 2022-08-30 南京佰麦生物技术有限公司 一种稳定的三水合盐酸伐地那非药物组合物
CN114246835A (zh) * 2022-01-05 2022-03-29 河北龙海药业有限公司 一种枸橼酸西地那非口腔崩解片的制备方法
CN115737581B (zh) * 2022-12-13 2024-03-12 上海普康药业有限公司 一种盐酸伐地那非口崩片及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006894A1 (de) * 2002-07-16 2004-01-22 Bayer Healthcare Ag Vardenafil hydrochlorid trihydrat enthaltende arzneimittel

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1049695T3 (da) 1997-11-12 2002-05-13 Bayer Ag 2-Phenyl-substituerede imidazotriazinoner som phosphodiesterase-inhibitorer
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
DE19944161A1 (de) * 1999-09-15 2001-03-22 Bayer Ag Neue Kombination zur Behandlung von sexueller Dysfunktion
DE102004023069A1 (de) 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
DE102005009241A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
AU2006298898B2 (en) * 2005-09-23 2011-06-30 F. Hoffmann-La Roche Ag Novel dosage formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006894A1 (de) * 2002-07-16 2004-01-22 Bayer Healthcare Ag Vardenafil hydrochlorid trihydrat enthaltende arzneimittel

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806314B2 (en) 2013-12-09 2023-11-07 Respira Therapeutics, Inc. PDE5 inhibitor powder formulations and methods relating thereto
US12364701B2 (en) 2013-12-09 2025-07-22 Respira Therapeutics, Inc. PDE5 inhibitor powder formulations and methods relating thereto

Also Published As

Publication number Publication date
EP2170296A2 (de) 2010-04-07
DE102007027067A1 (de) 2008-12-18
WO2008151811A2 (de) 2008-12-18
RU2010100819A (ru) 2011-07-20
US8772292B2 (en) 2014-07-08
CA2687500A1 (en) 2008-12-18
RU2493849C2 (ru) 2013-09-27
US20100159003A1 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
WO2008151811A3 (de) Verfahren zur herstellung eines arzneimittels enthaltend vardenafil hydrochlorid trihydrat
DK3872058T3 (en) Process for the preparation of 2,3,3,3 tetrahydrofluoropropene
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2008006979A3 (fr) Procede de preparation de composes diaminophenothiazinium.
WO2009085990A3 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
WO2009084024A3 (en) A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
WO2008037716A3 (en) Pharmaceutical compositions comprising nilotinib or its salt
WO2008003766A3 (en) 4-heter0cycl0alkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
WO2009006590A3 (en) Docetaxel process and polymorphs
WO2012047017A3 (ko) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
CL2007001006A1 (es) Compuestos derivados de piperidina u 8-aza-biciclo[3.2.1]octano sustituidos; formulacion farmaceutica; producto; y uso para el tratamiento o prevencion de enfermedades tales como diabetes mellitus no insulino dependiente, artritis, obesidad, dislipid
WO2008017381A8 (de) Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
WO2008152014A3 (en) 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
WO2008006795A3 (en) Indole compounds
WO2011023367A3 (en) Bisphosphonate-prodrugs
WO2012070062A3 (en) Novel polymorph of nilotinib hydrochloride
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2008001201A3 (en) Pharmaceutical compositions of clopidogrel
WO2010070677A3 (en) A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof
WO2007098273A3 (en) Novel crystalline forms of armodafinil and preparation thereof
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
WO2010079045A3 (en) Crystalline salt forms of flibanserine
WO2008009970A3 (en) Process for the preparation of montelukast
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
WO2007034279A3 (en) C3a antagonists and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08759223

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2687500

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 7951/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008759223

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010100819

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 12600446

Country of ref document: US